Fas-Ligand—Iron Fist or Achilles' Heel?

Suda, 1993, Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family, Cell, 75, 1169, 10.1016/0092-8674(93)90326-L Kagi, 1994, Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity, Science, 265, 528, 10.1126/science.7518614 Ju, 1994, Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells, Proc. Natl. Acad. Sci. USA, 91, 4185, 10.1073/pnas.91.10.4185 Stalder, 1994, Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity, J. Immunol., 152, 1127, 10.4049/jimmunol.152.3.1127 Ju, 1995, Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation, Nature, 373, 444, 10.1038/373444a0 Brunner, 1995, Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas, Nature, 373, 441, 10.1038/373441a0 Dhein, 1995, Autocrine T-cell suicide mediated by APO-1/Fas/CD95), Nature, 373, 438, 10.1038/373438a0 Suda, 1997, Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing, J. Exp. Med., 186, 2045, 10.1084/jem.186.12.2045 Schneider, 1998, Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity, J. Exp. Med., 187, 1205, 10.1084/jem.187.8.1205 Kischkel, 1995, Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor, EMBO J., 14, 5579, 10.1002/j.1460-2075.1995.tb00245.x Siegel, 2000, The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity, Nat. Immunol., 1, 469, 10.1038/82712 Budd, 2001, Activation-induced cell death, Curr. Opin. Immunol., 13, 356, 10.1016/S0952-7915(00)00227-2 Thome, 1997, Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors, Nature, 386, 517, 10.1038/386517a0 Irmler, 1997, Inhibition of death receptor signals by cellular FLIP, Nature, 388, 190, 10.1038/40657 Kataoka, 1998, FLIP prevents apoptosis by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation, J. Immunol., 161, 3936, 10.4049/jimmunol.161.8.3936 Bonfoco, 1998, Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells, Immunity, 9, 711, 10.1016/S1074-7613(00)80668-8 Griffith, 1995, Fas-ligand induced apoptosis as a mechanism of immune privilege, Science, 270, 1189, 10.1126/science.270.5239.1189 Griffith, 1996, CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance, Immunity, 5, 7, 10.1016/S1074-7613(00)80305-2 Bellgrau, 1995, A role for CD95 ligand in preventing graft rejection, Nature, 377, 630, 10.1038/377630a0 Stuart, 1997, CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival, J. Clin. Invest., 99, 396, 10.1172/JCI119173 Hahne, 1996, Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [see comments], Science, 274, 1363, 10.1126/science.274.5291.1363 O'Connell, 1996, The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand, J. Exp. Med., 184, 1075, 10.1084/jem.184.3.1075 Strand, 1996, Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—A mechanism of immune evasion?, Nat. Med., 2, 1361, 10.1038/nm1296-1361 Niehans, 1997, Human lung carcinomas express Fas ligand, Cancer Res., 57, 1007 Saas, 1997, Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?, J. Clin. Invest., 99, 1173, 10.1172/JCI119273 Bennett, 1998, The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma, J. Immunol., 160, 5669, 10.4049/jimmunol.160.11.5669 Restifo, 2000, Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape, Nat. Med., 6, 493, 10.1038/74955 Lau, 1996, Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice, Science, 272, 109, 10.1126/science.273.5271.109 Arai, 1997, Inhibition of the alloantibody response by CD95 ligand, Nat. Med., 3, 843, 10.1038/nm0897-843 Tourneur, 2001, Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts, J. Immunol., 167, 1338, 10.4049/jimmunol.167.3.1338 Zhang, 1999, Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells, J. Immunol., 162, 1423, 10.4049/jimmunol.162.3.1423 Matsue, 1999, Induction of antigen-specific immunosuppression by CD95L cDNA-transfected ‘killer’ dendritic cells, Nat. Med., 5, 930, 10.1038/11375 Min, 2000, Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival, J. Immunol., 164, 161, 10.4049/jimmunol.164.1.161 Allison, 1997, Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts, Proc. Natl. Acad. Sci. USA, 94, 3943, 10.1073/pnas.94.8.3943 Kang, 1997, Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction, Nat. Med., 3, 738, 10.1038/nm0797-738 Arai, 1997, Gene transfer of Fas-ligand induces tumor regression in vivo, Proc. Natl. Acad. Sci. USA, 94, 13862, 10.1073/pnas.94.25.13862 Seino, 1997, Antitumor effect of locally produced CD95 ligand, Nat. Med., 3, 165, 10.1038/nm0297-165 Miwa, 1998, Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand, Nat. Med., 4, 1287, 10.1038/3276 Shimizu, 1999, Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells, J. Immunol., 162, 7350, 10.4049/jimmunol.162.12.7350 Takeuchi, 1999, Accelerated rejection of Fas ligand-expressing heart grafts, J. Immunol., 162, 518, 10.4049/jimmunol.162.1.518 Turvey, 2000, Fas ligand-transfected myoblasts and islet cell transplantation, Transplantation, 69, 1972, 10.1097/00007890-200005150-00043 Hohlbaum, 2000, Opposing effects of transmembrane and soluble Fas-ligand on inflammation and tumor cell survival, J. Exp. Med., 191, 1209, 10.1084/jem.191.7.1209 Theofilopoulos, 1985, Association of lpr gene with graft-vs-host disease-like syndrome, J. Exp. Med., 162, 1, 10.1084/jem.162.1.1 Allen, 1990, Bone marrow transplantation from mutant lpr/lpr mice. Functional abnormalities rather than alloantigenic differences appear to determine the development of a graft-vs.-host-like syndrome, Eur. J. Immunol., 20, 2057, 10.1002/eji.1830200926 Kuwano, 1999, Essential roles of the Fas–Fas ligand pathway in the development of pulmonary fibrosis, J. Clin. Invest., 104, 13, 10.1172/JCI5628 Borges, 2001, Fas ligand triggers pulmonary silicosis, J. Exp. Med., 194, 155, 10.1084/jem.194.2.155 Seino, 1998, Chemotactic activity of soluble Fas ligand against phagocytes, J. Immunol., 161, 4484, 10.4049/jimmunol.161.9.4484 Ottonello, 1999, Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes, J. Immunol., 162, 3601, 10.4049/jimmunol.162.6.3601 Kang, 2000, A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants, Transplantation, 69, 1813, 10.1097/00007890-200005150-00014 Shudo, 2001, The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity, Eur. J. Immunol., 31, 2504, 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C Jodo, 2000, CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity, J. Immunol., 165, 5487, 10.4049/jimmunol.165.10.5487 Schaub, 2000, Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells, Nat. Med., 6, 790, 10.1038/77521 Tsutsui, 1999, Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice, Immunity, 11, 359, 10.1016/S1074-7613(00)80111-9 Rescigno, 2000, Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction. A new role for fas ligand in inflammatory responses, J. Exp. Med., 192, 1661, 10.1084/jem.192.11.1661 Abreu-Martin, 1995, Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen, J. Immunol., 155, 4147, 10.4049/jimmunol.155.9.4147 Sekine, 1996, Fas-mediated stimulation induces IL-8 secretion by rheumatoid arthritis synoviocytes independently of CPP32-mediated apoptosis, Biochem Biophys. Res. Commun., 228, 14, 10.1006/bbrc.1996.1610 Saas, 1999, CD95 (Fas/Apo-1) as a receptor governing astrocyte apoptotic or inflammatory responses: A key role in brain inflammation?, J. Immunol., 162, 2326, 10.4049/jimmunol.162.4.2326 Lee, 2000, Differential regulation and function of Fas expression on glial cells, J. Immunol., 164, 1277, 10.4049/jimmunol.164.3.1277 Daigle, 2000, Induction of the IL-10 gene via the fas receptor in monocytes—An anti-inflammatory mechanism in the absence of apoptosis, Eur. J. Immunol., 30, 2991, 10.1002/1521-4141(200010)30:10<2991::AID-IMMU2991>3.0.CO;2-1 Alderson, 1993, Fas transduces activation signals in normal human T lymphocytes, J. Exp. Med., 178, 2231, 10.1084/jem.178.6.2231 Kataoka, 2000, The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways, Curr. Biol., 10, 640, 10.1016/S0960-9822(00)00512-1 Rathmell, 1996, Expansion and elimination of B cells in vivo: Dual roles for CD40L- and Fas (CD95)-ligands modulated by the B cell antigen receptor, J. Exp. Med., 147, 1611 Aggarwal, 1995, Fas antigen signals proliferation of normal human diploid fibroblasts and its mechanism is different from tumor necrosis factor receptor, FEBS Lett., 364, 5, 10.1016/0014-5793(95)00339-B Owen-Schaub, 1993, Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin, J. Immunother., 14, 234, 10.1097/00002371-199310000-00011 Desbarats, 2000, Fas engagement accelerates liver regeneration after partial hepatectomy, Nat. Med., 6, 920, 10.1038/78688 Chaudhary, 1999, Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs, J. Biol. Chem., 274, 19211, 10.1074/jbc.274.27.19211 Chaudhary, 2000, Activation of the NF-kappaB pathway by caspase 8 and its homologs, Oncogene, 19, 4451, 10.1038/sj.onc.1203812 Hu, 2000, Activation of NF-kappaB by FADD, Casper, and caspase-8, J. Biol. Chem., 275, 10838, 10.1074/jbc.275.15.10838 Ting, 1996, RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis, EMBO J., 15, 6189, 10.1002/j.1460-2075.1996.tb01007.x Kelliher, 1998, The death domain kinase RIP mediates the TNF-induced NF-kappaB signal, Immunity, 8, 297, 10.1016/S1074-7613(00)80535-X Villunger, 2000, Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD, J. Immunol., 165, 1337, 10.4049/jimmunol.165.3.1337 Stanger, 1995, RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death, Cell, 81, 513, 10.1016/0092-8674(95)90072-1 Yang, 1997, Daxx, a novel Fas-binding protein that activates JNK and apoptosis, Cell, 89, 1067, 10.1016/S0092-8674(00)80294-9 Wajant, 2001, The TNF-receptor-associated factor family: Scaffold molecules for cytokine receptors, kinases and their regulators, Cell. Signal., 13, 389, 10.1016/S0898-6568(01)00160-7 Hohlbaum, 2001, Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors, J. Immunol., 167, 6217, 10.4049/jimmunol.167.11.6217